Insider Buying: Aldeyra Therapeutics (NASDAQ:ALDX) CEO Buys $417,500.00 in Stock

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) CEO Todd Brady acquired 250,000 shares of Aldeyra Therapeutics stock in a transaction that occurred on Wednesday, June 3rd. The stock was acquired at an average price of $1.67 per share, with a total value of $417,500.00. Following the completion of the acquisition, the chief executive officer directly owned 1,721,298 shares in the company, valued at $2,874,567.66. This represents a 16.99% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Aldeyra Therapeutics Stock Performance

Shares of NASDAQ:ALDX opened at $1.63 on Monday. The stock has a market capitalization of $98.32 million, a price-to-earnings ratio of -3.54 and a beta of 1.19. The stock’s 50-day simple moving average is $1.68 and its two-hundred day simple moving average is $3.67. Aldeyra Therapeutics, Inc. has a 52-week low of $1.07 and a 52-week high of $6.18.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its earnings results on Thursday, May 7th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.07. As a group, equities analysts forecast that Aldeyra Therapeutics, Inc. will post -0.43 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its position in shares of Aldeyra Therapeutics by 2.6% during the 3rd quarter. Vanguard Group Inc. now owns 3,591,869 shares of the biotechnology company’s stock valued at $18,750,000 after buying an additional 90,276 shares in the last quarter. 683 Capital Management LLC lifted its position in shares of Aldeyra Therapeutics by 86.6% during the 4th quarter. 683 Capital Management LLC now owns 1,530,000 shares of the biotechnology company’s stock valued at $7,925,000 after buying an additional 710,000 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Aldeyra Therapeutics by 275.4% during the 2nd quarter. AQR Capital Management LLC now owns 1,473,812 shares of the biotechnology company’s stock valued at $5,645,000 after buying an additional 1,081,257 shares in the last quarter. Kennedy Capital Management LLC lifted its position in shares of Aldeyra Therapeutics by 12.9% during the 4th quarter. Kennedy Capital Management LLC now owns 1,255,838 shares of the biotechnology company’s stock valued at $6,505,000 after buying an additional 143,625 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Aldeyra Therapeutics by 0.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,146,597 shares of the biotechnology company’s stock valued at $4,392,000 after buying an additional 8,769 shares in the last quarter. 59.71% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have issued reports on ALDX. Weiss Ratings cut Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 20th. Wall Street Zen raised Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. HC Wainwright reissued a “neutral” rating and issued a $2.00 target price (down from $10.00) on shares of Aldeyra Therapeutics in a research report on Wednesday, March 18th. Finally, BTIG Research reissued a “buy” rating on shares of Aldeyra Therapeutics in a research report on Tuesday, March 17th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $5.50.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.